PURPOSE: To evaluate the in vivo release and ocular toxicity of a tacrolimus-loaded PLGA intravitreal implant. METHODS: Tacrolimus-loaded PLGA implants were inserted into the vitreous cavity of rabbits' eye. At different time points, the vitreous was retrieved and the concentration of tacrolimus released from the implants was determined. Clinical examination was performed to evaluate the implant tolerance. RESULTS: PLGA implants provided controlled and prolonged release of tacrolimus. Approximately 99.97% of the drug was released from the devices at 6 weeks. Ophthalmic examination revealed no evidence of toxic effects of implants. CONCLUSIONS: Tolerance and feasibility of the tacrolimus-loaded PLGA implants, as sustained intraocular drug delivery systems, were demonstrated.
PURPOSE: To evaluate the in vivo release and ocular toxicity of a tacrolimus-loaded PLGA intravitreal implant. METHODS:Tacrolimus-loaded PLGA implants were inserted into the vitreous cavity of rabbits' eye. At different time points, the vitreous was retrieved and the concentration of tacrolimus released from the implants was determined. Clinical examination was performed to evaluate the implant tolerance. RESULTS: PLGA implants provided controlled and prolonged release of tacrolimus. Approximately 99.97% of the drug was released from the devices at 6 weeks. Ophthalmic examination revealed no evidence of toxic effects of implants. CONCLUSIONS: Tolerance and feasibility of the tacrolimus-loaded PLGA implants, as sustained intraocular drug delivery systems, were demonstrated.
Authors: Morgan V Fedorchak; Ian P Conner; Carlos A Medina; Jeremy B Wingard; Joel S Schuman; Steven R Little Journal: Exp Eye Res Date: 2014-06-28 Impact factor: 3.467
Authors: Paulina García-Estrada; Miguel A García-Bon; Edgar J López-Naranjo; Dulce N Basaldúa-Pérez; Arturo Santos; Jose Navarro-Partida Journal: Pharmaceutics Date: 2021-05-12 Impact factor: 6.321